Abstract: Systemic lupus erythematosus (SLE) is an archetype of systemic autoimmune disease characterized by the production of a broad spectrum of autoantibodies. More than 100 autoantibodies have been found in the sera of patients with SLE, including antibodies against nuclear, cytoplasmic, surface-membrane, and extracellular antigens. There has been considerable debate as to whether these antinuclear autoantibodies (ANAs) are merely biomarkers for disease or are responsible for organ/tissue damage in SLE. In recent years, sufficient evidence has supported the hypothesis that many ANAs, such as anti-double-stranded DNA (anti-dsDNA), antiribosomal P, anti-Sm, antiribonucleoprotein (anti-RNP), and even anti-Sjögren's syndrome (SS)-B/La antibodies not only act against specific nuclear antigens but also cross-react with different surface-expressed cognate molecules. The binding of autoantibodies to the cell surface leads to their penetration into the cell's interior to elicit cellular damage. There are at least four conceivable routes for ANAs to penetrate the cytoplasm: (1) nonspecific Fcγ receptor-mediated uptake, (2) cell-surface caveolae-mediated endocytosis, (3) electrostatic interactions between positively charged amino acids of the complementarity-determining regions of the antibody molecule and the negatively charged surface membrane, and (4) the binding of the autoantibody with its cross-reactive cell surface-expressed cognate molecule, and its subsequent endocytosis into the cytoplasm. In this review, we discuss in detail the immunopathogenic mechanisms of the commonly encountered ANAs, such as anti-dsDNA, antiribosomal P, and anti-SSB/La, that are associated with lupus pathogenesis. Additionally, the detrimental thromboembolisminducing anticardiolipin antibodies in patients with SLE were found to not only damage vascular endothelial cells, red blood cells, and platelets but also suppress lymphocyte proliferation, neutrophil phagocytosis, glomerular mesangial cell growth, and brain damage through their nonspecific membranotropic effects. For future clinical applications, useful biomarkers in SLE sera should be identified to determine disease susceptibility, diagnosis, activity evaluation, and specific organ damage.
Introduction
Systemic lupus erythematosus (SLE) is an archetype of chronic autoimmune disease with inflammation in various organs/tissues, especially the musculoskeletal, mucocutaneous, renal, and nervous systems (Table 1, our unpublished data). More than 100 different autoantibodies have been found in the serum of patients with SLE. 1 It is conceivable that the wide spectrum of clinical manifestations in patients with SLE is partially caused by pathogenic autoantibodies. The autoantibodies may potentially target their corresponding autoantigens in the cell nuclei, cytoplasm, cell-surface membrane, serum components, extracellular matrix substances, and miscellaneous molecules. The mechanism of production of the diverse spectrum of autoantibodies against self-antigens remains to be elucidated. However, many studies have demonstrated that autoantibody production might be antigendriven, 2 a result of polyclonal B-cell activation, 3 impaired apoptotic cell clearance, 4 or idiotypic network dysregulation in patients. 5 It is quite possible that polyclonal B-cell activation in SLE is derived from (1) defective B-cell tolerance in the bone marrow, 6 (2) somatic hypermutation during the germinal center reaction, 2 (3) B-cell epitope spreading after chronic stimulation, 7 and (4) impaired apoptotic cell clearance by phagocytes. These mechanisms can lead to nuclear antigen-driven autoantibody production. 8 On the other hand, increased cell destruction in patients with SLE by either cellular or antibody-mediated mechanisms concomitant with defective apoptotic cell clearance becomes a vicious cycle of the chronic immune dysfunction found in patients with SLE ( Figure 1 ). The increased cell apoptosis or eventual secondary necrosis in addition to defective cell debris clearance does not merely break down self-tolerance but also stimulates both innate and adaptive immune responses to induce florid autoantibody production. There are at least three defects involved in decreased apoptotic cell clearance in SLE: (1) congenital deficiency of complement components C2, C4, or C1q, 9 (2) production of autoantibodies against C-reactive protein and other acute-phase proteins, 10 and (3) production of anti-heat shock-protein autoantibodies. 11 The aforementioned molecules are crucial for tissue-debris opsonization and facilitate phagocytosis of the opsonized tissue debris or nuclear substances. Defective cell debris molecules engulfed by phagocytes eventually cause these denatured autoantigens to activate the innate and adaptive immune systems to produce autoantibodies.
Many studies have demonstrated that at least two unique properties are found in naturally occurring and pathogenic immunoglobulin (Ig) G autoantibodies compared to nonspecific IgGs: (1) polyreactivity or cross-reactivity results in an autoantibody being reactive with many different antigens, [12] [13] [14] [15] and (2) penetration of these antigen-driven autoantibodies into the cell interior. 16 Prabhakar et al 12 were the first authors to demonstrate that normal human B lymphocytes are capable of producing monoclonal autoantibodies reactive to different tissues/organs. Hurez et al 13 further demonstrated that polyreactivity or cross-reactivity is a characteristic of naturally occurring autoantibodies in the serum. In the physiological sense, these low-titer natural antibodies in the serum work as first-line defense molecules against microbial infections. However, an increasing number of observations have found that polyreactive autoantibodies in different autoimmune disorders indeed possess pathogenic potential to cause cell/ tissue damage. 14, 15 Many authors have demonstrated that the third complementarity-determining region (H-CDR3) of the immunoglobulin heavy chain and the N-terminal region contribute to differences in polyreactivity and monospecificity between natural and antigen-driven antibodies, respectively. [17] [18] [19] Weller et al 20 further demonstrated that terminal deoxynucleotidyl transferase can mediate N-region diversity (polyreactivity) and affect the affinity of anti-DNA autoantibodies in mice.
Alarcón-Segovia et al 21 were the first to demonstrate that the penetration of autoantibodies into cells may induce autoimmune disease via cell damage and immune dysregulation. The same group further reported that most anti-DNA antibodies penetrate large proportions of live immature cells, and not normal adult cells, to elicit cell apoptosis. 22 Although pathogenic autoantibodies play an important role in cell/tissue damage, many other factors derived from abnormal immune responses, including proinflammatory cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-17, tumor necrosis factor [TNF]-α, different colony-stimulating factors, and macrophage-stimulating factors), O 2 radicals, nitric oxide, released proteolytic enzymes, immune complexes, (ICs), and T cell-mediated autoimmune reactions, may also be implicated in lupus pathogenesis and sustain chronic tissue inflammation. Among these, complement fixed-IC-induced cell/tissue inflammation via complement receptors on the cell surface were an important pathogenic mechanism of antinuclear autoantibodies (ANAs). The IC mechanism may include IC formation in the blood (circulatory ICs) and in situ IC formation in tissues. 
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However, it is quite difficult to confirm directly the presence of autoantigens in the circulating ICs in the serum. The in situ formation of ICs also depends on surface-expressed specific autoantigens, molecular mimic antigens, or electrostatic interactions between positively charged antibodies and negatively charged molecules in the tissues. It is believed that some of the ANAs are pathogenic, whereas some of them are nonpathogenic. The conflicting results in the literature may depend on the properties of the ANAs. Only the high titer of ANAs cannot reflect the degree of tissue damage in patients with SLE. Furthermore, the clearance capacities of ICs as well as tissue debris by macrophages, dendritic cells, neutrophils, and reticuloendothelial systems in patients with SLE are defective. Therefore, excessive ICs and cell debris such as nucleosomes, denatured deoxyribonucleoproteins, and denatured ribonucleoproteins may bind to endosomal Toll-like receptors (TLR3, -7, and -9) and nucleotide-binding oligomerization domain-like receptors in the macrophage/ dendritic cells to stimulate ANA production. These potential pathogenic factors and their deleterious reactions are depicted in Figure 1 .
It has been a long-standing debate as to whether the broad spectrum of autoantibodies are culprits or merely innocent bystanders as disease biomarkers in patients with SLE. [23] [24] [25] [26] [27] Evidence supports that both possibilities coexist, because some of them are good biomarkers for disease susceptibility and diagnosis, whereas others play pathogenic roles in SLE via their cell-penetrating ability into the cytoplasm to induce cell damage ( Table 2) . In this review, we extensively discuss the immunopathogenic roles of the four [58] [59] [60] [61] [62] [63] Thromboembolism Anticardiolipin [58] [59] [60] [61] [62] [63] Habitual abortion and fetal loss Anticardiolipin [58] [59] [60] [61] [62] [63] Notes: *Anti-α-actinin, antilaminin, antifibronectin, antimyosin, and anticollagen; **anti-N-methyl-d-aspartate receptor subtypes 2a and 2b on neuronal cells. Abbreviations: dsDNA, double-stranded DNA; SS, Sjögren's syndrome; NPSLe, neuropsychiatric systemic lupus erythematosus; RBC, red blood cell.
commonly encountered autoantibodies in clinical practice, including anti-double-stranded DNA (anti-dsDNA), anticardiolipin antibody (ACA), antiribosomal P protein (anti-RP), and anti-Sjögren's syndrome (SS)-B/La antibodies in lupus pathogenesis.
Different autoantibodies can be used as specific biomarkers of SLE in different clinical categories
In 1997, the American College of Rheumatology revised the classification criteria for SLE, suggesting that anti-dsDNA, ACA, and anti-Sm antibodies can be used as diagnostic biomarkers for SLE. 28 In daily practice, the titer of anti-dsDNA, antinucleosome, and antinucleoside/antinucleotide antibodies, if applicable, can be used as disease-activity biomarkers in SLE. 1, 29, 30 These autoantibody biomarkers are more convenient in daily practice than complex global evaluation scores, such as the SLE Disease Activity Index 31 or the British Isles Lupus Activity Group assessment 32 for evaluating SLE serological changes, but not for systemic tissue/organ-damage evaluation. Undoubtedly, many autoantibodies are regarded as surrogate biomarkers for specific organ/tissue damage in patients with SLE. Table 3 lists some of the potential autoantibody biomarkers used in different clinical categories of patients with SLE. Among these, anti-dsDNA antibodies can be used as specific biomarkers for disease diagnosis, disease activity, and lupus nephritis. Anti-C1q autoantibodies can be used for concurrent evaluation of both renal 33 and extrarenal 34 disease activity in SLE. However, anti-C1q antibodies can also be detected in sera from patients with hypocomplementemic urticarial vasculitis. 35 Consequently, the sensitivity and specificity of anti-C1q antibodies in evaluating SLE disease activity should be reconsidered.
One particular pathogenic autoantibody can exert deleterious effects on different organs or tissues via cross-reactivity. A representative example demonstrates that anti-dsDNA 
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Autoantibodies in SLe can induce nephritis, hepatitis, neutropenia, lymphopenia, and even neuropsychiatric lupus (NPSLE) in patients with SLE. 1, 22, 26, 36 Conversely, an organ/tissue can be the target of different kinds of autoantibodies. NPSLE in patients with SLE is the typical case in which the organs are attacked by at least four types of autoantibodies, including antineuronal, antiribosomal P, anticardiolipin, and antiendothelial cell antibodies. Diamond and Volpe 36 demonstrated that anti-dsDNA and antipeptides bind N-methyl-d-aspartate (NMDA) receptor 2 (NR2) on neurons can directly mediate NPSLE, but they do not depend on IC formation when the blood-brain barrier is impaired. Obviously, the crossreactivity of an ANA can directly mediate cell/tissue damage through cell surface-expressed cognate antigens in systemic autoimmune diseases. 37 Table 4 shows that polyclonal or monoclonal anti-dsDNA autoantibodies bind to different surface-expressed cognate molecules via cross-reactivity, electrostatic interactions with structural proteins, or other undefined mechanism(s) to exert different immunopathogenic effects in patients with SLE.
Autoantibody testing has been commonly used in the diagnosis and follow-up evaluation of patients with systemic rheumatic diseases. More detection methods have been developed in addition to the classical immunofluorescence anti-nuclear antibody test by using HEp-2 as the cell substrate and Western blotting. Enzyme-linked immunosorbent assay (ELISA) and an automatic bead-based ANA screening assay were successively applied for autoantibody quantification in clinical practice. Many authors found that the measurement of autoantibodies by using automatic multiplex methodology in patients with SLE was equally sensitive and highly specific compared to conventional ELISA. [38] [39] [40] Recently, Eriksson et al 41 found that autoantibodies against nuclear antigens, particularly SSA/Ro and dsDNA, could be detected before the onset of SLE. The first autoantibody detected was anti-SSA/Ro, and the highest predicted odds ratio was conferred by anti-dsDNA antibodies.
Immunopathogenic roles of anti-dsDNA antibodies in lupus pathogenesis
Polyclonal anti-dsDNA antibodies purified from active SLE sera by λ-phage DNA-affinity chromatography suppress mitogen-activated T-lymphocyte proliferation, but elicit biphasic immunoglobulin synthesis by activated B lymphocytes, as shown in our previous study. 42 These functional changes by anti-dsDNA antibodies resemble immune disorders in patients with SLE. SLE-derived polyclonal anti-dsDNA antibodies were also shown to be nephrotropic and could directly damage the glomerular mesangial cells (GMCs) through binding to the surface-expressed acidic ribosomal phosphoproteins P0 (38 kDa), P1 (19 kDa), and P2 (17 kDa). 43, 44 These results are partially consistent with the findings by Du et al, 45 indicating that nine affinitypurified anti-dsDNA autoantibodies cross-reacted with cell membrane-expressed 74 kDa, 63 kDa, and 42 kDa molecules. Yung et al 46, 47 demonstrated that anti-dsDNA antibodies bound to annexin II molecules on human GMCactivated p38 mitogen-activated protein kinase (MAPK), Jun, AKT, protein kinase C-α, and protein kinase C-β signaling pathways to induce IL-6, transforming growth factor-β 1 , fibronectin, and annexin II synthesis. In contrast, Fenton et al 48 suggested that chromatin in circulating blood is important for glomerular mesangial matrix IC deposition for the occurrence of lupus nephritis. In addition to lupus nephritis, we found that anti-dsDNA autoantibodies also targeted P0 and P1 molecules expressed on different tissues of normal and autoimmune mice, such as in the liver, spleen, brain, and fibroblasts. 49 The cross-reactivity between anti-dsDNA and surface-expressed P1 protein relies on the C-terminal hydrophobic cluster region containing a phenylalanine residue. 50 Interestingly, a monoclonal anti-DNA antibody was shown to penetrate immature lymphoid cells more than their mature counterparts, and induced cell apoptosis, self-tolerance, or an autoimmune response depending upon the degree of immune dysregulation. 21, 22 These findings may become the molecular basis of the positive correlation between serum titers of antidsDNA and disease activity of SLE. 49 Functional assessments 54 demonstrated that a monoclonal anti-dsDNA antibody inhibited IL2 gene expression in a Jurkat T-cell line by activating phosphorylated glycogen synthase kinase 3, which mimics T-cell hyporesponsiveness in patients with active SLE. 42 Genetic manipulation by transgenic overexpression of anti-dsDNA autoantibodies and TLR4 activation in mice induced severe SLE syndrome. 55 Despite the cross-reactivity of anti-dsDNA antibodies with surface-expressed cognate molecules, it remains possible that the binding of anti-dsDNA to the cell surface is mediated by electrostatic interactions between the positively charged arginine residues in the CDRs of the IgG antibody F(ab')2 domain with the negatively charged surface membrane. 56 Alternatively, the IgG isotype autoantibody nonspecifically binds to the Fcγ receptor on the cell surface, and subsequently the ligand-receptor conjugates are taken up by endocytosis. 57 A schematic illustration of the immunopathogenic effects of anti-dsDNA on lupus pathogenesis is shown in Figure 2 .
Immunopathogenic roles of anticardiolipin antibodies on brain damage and immune dysfunctions in patients with SLE
It is conceivable that antiphospholipid antibodies (aPLs) contain anti-cell surface phospholipids, such as phosphatidylcholine, phosphatidylserine, and phosphatidyl-ethanolamine (detected by ELISA); anticardiolipin antibodies (detected by ELISA); and lupus anticoagulants (detected by their ability to prolong certain in vitro phospholipid-restricted bloodclot tests). Pathogenic aPLs are catastrophic autoantibodies that induce antiphospholipid syndrome (APS), which is relevant to a broad spectrum of thromboembolic disorders, hematological cytopenia, and habitual abortion in patients with SLE. [58] [59] [60] [61] [62] [63] Pathogenic aPLs can bind to both PLs and plasma cofactors, among which β 2 -glycoprotein I (β 2 GPI) is the most crucial factor. In an animal model, anti-β 2 GPI antibodies from patients with antiphospholipid syndrome were sufficient to potentiate arterial thrombus. 64 In contrast, influenza vaccination was shown to induce anticardiolipin but not β 2 GPI antibodies, and was not found to be pathogenic to the patients. 65 Annexin A5 is an important member of the annexin family with antithrombotic properties. This molecule has been implicated in SLE, because aPL interferes with its functions and causes thromboembolism and miscarriages in patients with SLE. 66, 67 Lin et al 68 reported that some aPLs recognized conformational epitopes shared by β 2 GPI and the homologous catalytic domains of many serine proteases. In a series of investigations on thrombotic mechanisms elicited by aPLs, Meroni et al 69 found that sophisticated processes were involved. These processes included disruption of fluid-phase coagulation, disruption of coagulation cell functions, and complement activation. Subsequently, Misra et al 70 determined that the activation of lymphocytes was mandatory for the expression of binding epitopes for ACAs on the cell surface. We purified ACAs from ACA + SLE sera following their methodology, and found that these particular autoantibodies possessed inhibitory activities on lymphocyte proliferation and polymorphonuclear cell (PMN) phagocytosis. 71 Furthermore, these SLE-derived ACAs bound to a rat brain astrocyte cell line and inhibited their proliferation in an in vitro experiment.
72 Surprisingly, intravenously injected ACAs entered brain tissue and bound to neurons, glial cells, and nerve fibers in an in vivo study. 73 These observations suggest that ACAs possess a potential capacity to damage the blood-brain barrier, penetrate brain tissue, and exert deleterious effects in NPSLE. 
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Tsai et al 73 also demonstrated that ACAs induced apoptosis of GMCs in addition to vascular coagulopathy in lupus nephropathy. Taking these findings together, we can conclude that ACAs exert potent immunosuppressive effects and play a role in NPSLE through their nonspecific membranotropic properties. A proposed schema illustrating the immunopathogenic effects of ACAs on lupus tissue damage is shown in Figure 3 .
Immunopathogenic effects of antiribosomal P autoantibodies on lupus psychosis and T-lymphocyte derangement
Autoantibodies against acidic ribosomal P have been demonstrated in 13%-20% of patients with SLE, and levels correlated with psychosis, nephritis, hepatitis, skin manifestations, and general disease activity. [74] [75] [76] However, their effects on immune functions and the molecular basis for their activities have not been elucidated.
Sun et al 77 reported that a monoclonal anti-human ribosomal P protein was involved in the pathogenesis of lymphopenia and lymphocyte dysfunction in SLE by penetrating living cells. The same group further demonstrated that this monoclonal antibody inhibited the release of IL-12, TNF-α, and inducible nitric oxide synthase in an activated mouse RAW 264.7 macrophage cell line. 78 In contrast, the monoclonal autoantibody also triggered immunosuppressive IL-10 overproduction via phosphatidylinositide 3-kinase (PI3 K)-dependent signaling pathways in lipopolysaccharideactivated macrophages. 79 These diverse immunological effects likely implicate a role for antiribosomal P antibodies in lupus pathogenesis. 76 In addition to antiribosomal P and anti-dsDNA, 36 other autoantibodies are potentially involved in NPSLE, including antibodies against endothelial cells, 77 neuronal NMDAreceptor subtypes 2a and 2b (anti-NR2 antibodies), 36 glial fibrillary acid protein, microtubule-associated protein 2, and matrix metalloproteinase 9.
80,81 A schema demonstrating the immunopathogenic effects of antiribosomal P antibodies on T cells and macrophages is shown in Figure 4 .
Immunopathological effects of anti-SSB/La autoantibodies on neutrophil functions
Neonatal lupus erythematosus has a clinical spectrum of cutaneous, cardiac, and some systemic manifestations in newborn infants whose mother produces antibodies against intracellular soluble ribonucleoproteins 48 kDa SSB/La, 52 kDa SSA/ Ro, or 60 kDa SSA/Ro. 82 However, only 1%-2% of mothers with these autoantibodies deliver neonates with lupus erythematosus, regardless of being healthy or symptomatic. 83 Li et al 84 from patients with SS to demonstrate a cross-reaction with cardiac sarcolemmal laminin. These data suggest that molecular mimicry between laminin and SSB/La exists. Anti-SSB/ La antibodies may play a crucial role in the pathogenesis of newborn congenital heart block. Reed et al 85 further found that Ro60 requires γ3 RNA for cell-surface exposure and inflammation in atrioventricular nodes, the cardiac conducting system, or the myocardium of neonatal lupus. In contrast, neutropenia and lymphocytopenia are hematological abnormalities in patients with SLE that are correlated with disease activity and are responsible for morbidity/mortality. 86 Anti-SSB/La appeared in 87% of patients with primary SS in association with leukopenia and lymphopenia. 87 Hsieh et al 88 found that anti-SSB/La antibodies purified from active SLE sera were able to penetrate into cells responsible for neutropenia and functionally impair PMNs via activation-induced cell apoptosis. Subsequently, Biswas et al 89 confirmed that the presence of anti-SSB/La was associated with defective neutrophil phagocytosis in patients with SLE. In addition, anti-SSB/La antibodies were shown to promote TNF-α secretion from macrophages. 90 Increased apoptosis superimposed on defective clearance of apoptotic cells rendered the released chromatins from PMN apoptotic blebs to be more immunogenic. These denatured chromatin molecules were finally taken-up by myeloid dendritic cells, which bound to endosomal TLR3, TLR7, and TLR9. These three TLRs are endosomal receptors for binding with dsRNA, ssRNA and dsDNA for immune reactions. In addition to apoptotic blebs, neutrophil extracellular traps (NETs) released from dying neutrophils in a process called NETosis may be a major source of autoantigens. Overactive NETosis may become a source in lupus pathogenesis. 91, 92 Obviously, anti-SSB/La autoantibodies play a crucial role in overactive NETosis. The immunopathogenic effects of anti-SSB/La autoantibodies on lupus pathogenesis are illustrated in Figure 5 .
In a recent study, Wu et al (unpublished data) found that exogenous SSB/La per se or SSB/La-anti-SSB/La ICs could potently activate IL-8 production and phagocytosis of PMNs as well as anti-SSB/La autoantibodies through PI3 K and MAPK signaling pathways. It was concluded that the SSB/ La-anti-SSB/La system may play a complex role in autoimmune pathogenesis.
Conclusion
Breakdown of self-tolerance to nuclear antigens and polyclonal B-cell activation render the production of a number of autoantibodies in patients with SLE. Some of these autoantibodies, such as anti-dsDNA, antiribosomal P, anticardiolipin, and anti-SSB/La, are indeed pathogenic, as they bind to surface-expressed cross-reactive antigens through electrostatic interactions or establish nonspecific FcγR binding to allow penetration into the cell's interior. These pathogenic autoantibodies not only directly damage the tissues to promote the release of more nuclear antigens, but derail innate and adaptive immune functions. The vicious cycle caused by these pathogenic autoantibodies sustains the chronic immunological and inflammatory abnormalities in patients with SLE. 
